Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,579 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Interventions: Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s); Drug · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 17 more

Conditions: Contact Dermatitis, Allergy; Dermatitis, Dermatitis
Interventions: Sensitivity Patch Testing; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pancreatic Neoplasms, Pancreatitis, Pancreatic Cyst
Interventions: EUS enhanced with contrast to evaluate pancreas; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson Disease
Interventions: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch; Drug · Other
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Idiopathic Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more

Conditions: Pancreatic Tumors
Interventions: Standard, Fanning; Procedure
Lead sponsor: Shyam Varadarajulu; Other
Eligibility: 19 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Rhytidoplasty
Interventions: clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane; Drug · Device
Lead sponsor: Mercy Facial Plastic Surgery Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Breast Cancer
Interventions: EnVisio SmartClip, EnVisio™ Navigation System; Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions: Nano-Pulse Stimulation Device; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more

Conditions: Smoking Cessation
Interventions: Nicotine patch, Nicotine gum, Medication Therapy Management; Drug · Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Ankle Sprain
Interventions: Esflurbiprofen Hydrogel Patch; Drug
Lead sponsor: Teikoku Seiyaku Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Chronic, Pain, Joint, Pain Syndrome
Interventions: transdermal cream and or patch; Combination Product
Lead sponsor: Data Collection Analysis Business Management; Other
Eligibility: 18 Years to 64 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Land O' Lakes, Florida

Conditions: Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions: Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions: SIRPant-M, External-beam radiotherapy (XRT); Biological · Radiation
Lead sponsor: SIRPant Immunotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Duarte, California • Hackensack, New Jersey • Houston, Texas

Conditions: Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
Interventions: Icapamespib; Drug
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New York, New York + 2 more

Conditions: Arthroplasty, Replacement, Shoulder
Interventions: Regeneten, Standard repair; Device · Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions: VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000; Biological · Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more

Conditions: Esophageal Neoplasm, Esophageal Polyp, Endoscopic Submucosal Dissection, Bipolar Electrocautery
Interventions: Speedboat™ Ultraslim; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: Alzheimer Disease
Interventions: F 18 T807 Flortaucipir; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Breast Diseases
Interventions: Evaluation of BIT-Motion software; Diagnostic Test
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Patient
Interventions: Hyperspectral Endoscopy (HySE), White Light Endoscopy (WLE); Procedure · Device
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Skin Cancer
Interventions: Optical Spectroscopy; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Search by objective public record fields.

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Study on Hypoallergenic Hair Dye

Contrast EUS of the Pancreas

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)

Anesthetics in Rhytidoplasty - A Comparison Study

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

QuitAid Pilot Feasibility Trial

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain

Subjective Observational Study of Patients Using Transdermal Cream Medication And/Or Transdermal Patches With Or Without Oral Non-Narcotic Medications

Iontophoresis in Psoriasis

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

Evaluation of Regeneten Augmentation for Subscapularis Healing After Total Shoulder Arthroplasty (RESTOR)

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

EverFlex Post Approval Study

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

Advanced Diffusion Tensor MRI for Breast Cancer

Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions